OpenAI Researcher Miles Wang Plans AI Drug Discovery Startup

Miles Wang, an OpenAI researcher, is reportedly preparing to launch a startup focused on applying AI models to identify new applications for existing pharmaceutical drugs.

Startups, Policy & World Desk
Updated Nov 10, 2026 2 min read
OpenAI Researcher Miles Wang Plans AI Drug Discovery Startup

Miles Wang, an OpenAI researcher known for his work on using artificial intelligence to accelerate scientific discovery, is reportedly preparing to launch a new startup. According to TechCrunch, Wang is in the process of leaving the ChatGPT maker to develop AI models specifically for the pharmaceutical sector. While specific technical details of the platform remain unconfirmed, sources indicate the company may focus on identifying new uses for existing drugs, including those that previously failed during clinical trials. This strategy aims to leverage medicines that have already cleared safety testing, potentially offering a faster route to market compared to developing new compounds from scratch.

Wang’s departure follows his tenure at OpenAI, which he joined in 2024 after leaving a computer science program at Harvard. During his time at the company, he co-authored research papers examining how AI models can automate and speed up scientific research. His new venture is expected to include other researchers from OpenAI, signaling a continued migration of talent from generative AI labs toward specialized vertical applications in biology and medicine. Wang has disputed the specific figures and descriptions of the company reported by TechCrunch, though he did not provide alternative details regarding his plans.

The startup enters a crowded and well-capitalized field where AI is being positioned as a solution to the inefficiencies of traditional drug discovery. The sector has seen substantial capital inflows recently; for instance, Chai Discovery, a two-year-old company also founded by a former OpenAI researcher, recently raised $400 million at a $3.8 billion valuation to build models that predict molecular interactions. Similarly, Isomorphic Labs, a spinout from Google DeepMind, secured a $2.1 billion Series B round in May. These moves highlight a broader industry trend of applying large-scale machine learning to biological data.

While the promise of AI in drug discovery is significant, the industry remains in a phase of high-stakes experimentation. The core value proposition for these startups is the ability to analyze biological data at a scale and speed that traditional pharmaceutical R&D pipelines cannot match. By predicting how molecules interact or identifying overlooked therapeutic applications for approved drugs, these companies aim to reduce the time and cost associated with bringing treatments to patients. Whether Wang’s platform can successfully translate these computational models into tangible, regulatory-approved medical breakthroughs remains the central question for the industry.

Investors are clearly betting on the potential for AI to disrupt these conventional pipelines, though the actual efficacy of these models in real-world clinical settings is still being tested. As of mid-July, discussions regarding the startup's funding remain ongoing, and details surrounding the company's final structure and technical roadmap are subject to change. For now, the move underscores the ongoing shift of AI research talent toward high-value, complex scientific problems, with the life sciences sector serving as a primary target for the next generation of machine learning applications.

Sources

  1. 01 OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B — TechCrunch